
Company Spotlight: iSchemaview Rapid MLS - Automating Brain Midline Shift on CT
We review the FDA 510(k) summary for iSchemaview's Rapid MLS, an AI software designed to measure brain midline shift from non-contrast CT scans. The episode unpacks the algorithm's performance against human experts, its clinical indications for intracranial hemorrhage and TBI, and the regulatory strategy of claiming substantial equivalence to a heart measurement tool.
Key points
- Rapid MLS uses AI/ML to measure brain midline shift on non-contrast CTs, providing a color overlay and quantitative JSON output.
- The software was cleared via the 510(k) pathway by claiming substantial equivalence to a predicate device that measures heart ventricles from CT pulmonary angiography (Rapid RV/LV).
- In final performance validation on 153 cases, Rapid MLS achieved a mean absolute error of 0.7 mm, compared to the 3 experts' average pairwise error of 1.0 mm.
- Validation data included a demographic split of 44% male and 56% female, spanning ages 26-93 years, sourced from 13 independent sites.
- The device is not intended for stand-alone clinical decision-making and remains restricted to sale by or on the order of a physician.
Source: FDA 510(k) summary K243378: Rapid MLS (iSchemaview) - U.S. Food and Drug Administration, 2025
This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.
Company: iSchemaview (ischemaview.com) · Product: Rapid MLS · FDA 510(k) K243378
Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-ischemaview-rapid-mls-automating-brain-midline-shift-a59fcb
Więcej odcinków z kanału "AI in Medicine - curated summaries making complex issues easy to understand"



Nie przegap odcinka z kanału “AI in Medicine - curated summaries making complex issues easy to understand”! Subskrybuj bezpłatnie w aplikacji GetPodcast.








